AI Analyst Summary
Elevance Health presents a recovery-oriented value play in managed care, trading at a forward P/E of just 13.2x as analysts broadly expect margin normalization after an industry-wide medical cost spike. The 15-Buy / 0-Sell analyst consensus and a perfect 4-of-4 recent EPS beat rate underscore confidence in management's near-term execution, even as YoY earnings contracted 13.1%. The central risk is that medical cost ratios remain stubbornly elevated, prolonging the earnings trough and delaying the recovery that current valuations are pricing in.
Fundamentals
Pe
Trailing P/E 17.7x / Forward P/E 13.2x · 4.0/5
Trailing P/E of 17.7x is modest for a large-cap managed care name, and the forward P/E of 13.2x implies meaningful earnings recovery expected ahead. Valuation sits below the broader healthcare sector median, offering a constructive entry point relative to peers.
Peg
PEG 1.42 · 3.0/5
PEG of 1.42 is moderate — above the 'undervalued' threshold of 1.0 but well below the 3.0 danger zone. Reflects a fair price for near-term growth expectations, though the current earnings contraction tempers enthusiasm.
Analyst Rating
Buy consensus (1.8) · 4.0/5
Consensus rating of 1.8 across 21 analysts (15 Buy / 7 Hold / 0 Sell) reflects strong institutional conviction. No sell-side bears and a majority Buy stance signal broad confidence in the recovery thesis, comfortably mapped to a score of 4.
Earnings Trend
EPS Growth YoY: -13.1% | Revenue Growth: +1.4% · 2.0/5
Year-over-year earnings contraction of -13.1% is a meaningful red flag, driven by elevated medical cost ratios pressuring managed care margins. Revenue growth of just 1.4% adds limited offset. The trend is deteriorating rather than stabilizing, though analyst consensus anticipates a forward recovery reflected in the 13.2x forward P/E.
Price Target Beat
4 of 4 quarters beat (last 4 reported) · 4.0/5
A perfect 4-for-4 EPS beat rate over the most recent quarters demonstrates reliable execution against expectations. While the full 8-quarter history is not provided, this recent consistency is a constructive signal and earns a score of 4, capped by limited historical depth.
Management
Consistent near-term execution; navigating medical cost headwinds · 3.0/5
Management has delivered on quarterly EPS expectations consistently in recent periods, which is commendable given the industry-wide medical cost pressure environment. However, the -13.1% earnings decline and modest revenue growth suggest strategic headwinds that limit a higher score. Capital allocation and operational discipline remain adequate but not exceptional given current results.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.